Satsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 9, 2021 San Francisco Biotechnology Network News News Comments Off on Satsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its...

Click to view original post

Related Articles

No Picture
News

Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors

October 13, 2021 San Francisco Biotechnology Network News News Comments Off on Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic produc… […]